BioMarin Pharmaceutical

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307. The company was founded by John C. Klock, Christopher M. Starr and Grant W. Denison on March 21, 1997, and is headquartered in San Rafael, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

BioMarin excels in Q4 with record revenues and gene therapy launch

BioMarin Pharmaceutical reported strong financial results in Q4 2022, achieving revenue growth, profitability, and successful introduction of the ROCTAVIAN gene therapy for hemophilia A.
The company's performance highlights its R&D capabilities, market positioning, and strategic readiness for upcoming product launches, positioning BioMarin for continued growth and innovation.
While facing challenges in reimbursement processes and regulatory requirements, BioMarin has opportunities to drive revenue expansion, market penetration, and address unmet medical needs through its innovative pipeline.

BioMarin reports strong Q1 earnings, eyes blockbuster status for ROCTAVIAN

BioMarin Pharmaceuticals had a robust Q1 2023, focusing on revenue growth, profitability, and commercial readiness for key drug launches. While facing challenges in Germany, the company is optimistic about the potential of ROCTAVIAN and VOXZOGO in driving future growth.

BioMarin excels in Q2 with record revenues and treatment milestones

BioMarin's strong Q2 performance, driven by record revenues and product demand, positions the company for growth.
Challenges like supply issues and site readiness are being addressed, while opportunities in new programs and markets are promising.
Overall, BioMarin's focus on compliance, expansion, and pipeline development sets a positive trajectory for future success.

BioMarin reports strong Q3 revenue growth, eyes Roctavian expansion

BioMarin's Q3 performance showed revenue growth driven by Voxzogo, with strong expectations for 2024 revenue.
New CEO Alexander Hardy is set to continue the core strategy, focusing on Roctavian's global launch and Voxzogo's growth potential.
Challenges include delays in Roctavian's takeoff and supply constraints for Voxzogo, but efforts are underway to address these issues.
Opportunities lie in Roctavian's revenue contribution, Voxzogo's U.S. growth potential, and leveraging CNP for stature improvements.

BioMarin posts robust Q4 earnings, eyes expansion in gene therapy

BioMarin Pharmaceutical delivered strong financial results in Q4 2023, driven by revenue growth and increased earnings per share. The company's focus on high-impact medicines and gene therapy expertise positions it well for future growth.
While facing challenges related to analyst inquiries and market adoption of key products like Roctavian and Voxzogo, BioMarin remains committed to innovation and optimizing its business model.
Opportunities lie in expanding product reach, maximizing shareholder value through strategic capital allocation, and driving innovation in transformative programs. BioMarin's long-term strategy and growth potential remain promising.

BioMarin reports record revenue, focuses on key assets for growth

BioMarin Pharmaceutical's Q1 2024 performance reflects strong revenue growth and financial stability, driven by key product demand.
While facing challenges such as revenue impact and supply constraints, the company's strategic focus on key assets and cost reduction initiatives bode well for future growth.
Opportunities lie in expanding Voxzogo's market reach, optimizing manufacturing capabilities, and maintaining a competitive edge in innovative treatments.

BioMarin Pharmaceuticals reports record revenue and profitability outlook for 2024

BioMarin Pharmaceuticals delivered strong financial performance in Q2 2024, driven by robust revenue growth and strategic decisions. The company's focus on profitability, expansion of key treatments, and progress in R&D highlight a promising outlook. Addressing analyst inquiries and leveraging upcoming events can further enhance investor confidence and market positioning.

BioMarin reports record Q3 revenues, eyes long-term growth targets

BioMarin Pharmaceuticals showcased robust financial performance and raised full-year guidance.
The company remains optimistic about its long-term growth prospects and is committed to defending its IP.
Strategic focus on expanding global reach and driving growth in enzyme therapies portfolio.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

It's bad news for hemophilia A sufferers in the U.S., and for the company's shareholders.

FDA Rejects BioMarin's Hemophilia Gene Therapy

BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) stock was crushed on Wednesday after the company announced that the U.S.

What This FDA Response Means for BioMarin’s Gene Therapy for Hemophilia

Shares of BioMarin Pharmaceutical Inc. BMRN, -30.76% tumbled 27.6% in trading on Wednesday after the company said it had received a complete response letter from the Food and Drug Administration for its experimental hemophilia A treatment.

BioMarin's stock falls 27% after FDA asks for additional data about experimental hemophilia A drug

BioMarin Pharmaceutical on Wednesday said the U.S. Food and Drug Administration wants more data on its hemophilia A gene therapy.

BioMarin Handed Setback By FDA On Hemophilia Drug; BMRN Stock Plunges

FDA Introduces New Recommendation for 2-Year Annualized Bleeding Rate (ABR) as Primary Endpoint for Ongoing Phase 3 Study 270-301

BioMarin Receives Complete Response Letter (CRL) from FDA for Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A

The EMA sanctions BioMarin's (BMRN) marketing authorization application for vosoritide to treat children with achondroplasia, the most common type of dwarfism.

BioMarin's MAA for Dwarfism Candidate Gets EMA Validation

Is  (BMRN) Outperforming Other Medical Stocks This Year?

Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?

BioMarin (BMRN) reports better-than-expected second-quarter results. The company maintains its previously issued guidance for 2020.

BioMarin (BMRN) Q2 Earnings Top, Sales Show Coronavirus Impact

Two of the biotech's drugs performed especially well in the second quarter.

How Biomarin Beat Expectations in Q2

BioMarin Pharmaceutical Inc.'s (BMRN) CEO Jean-Jacques Bienaimé on Q2 2020 Results - Earnings Call Transcript

BioMarin (BMRN) delivered earnings and revenue surprises of 100.00% and 2.74%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Beat Estimates

SAN RAFAEL, Calif., Aug. 4, 2020 /PRNewswire/ -- Financial Highlights (in millions of U.S.

BioMarin Announces Second Quarter 2020 Total Revenue Growth of 11% to $430 million

Biomarin Pharmaceutical (NASDAQ: BMRN) will be releasing its next round of earnings this Tuesday, August 04.

Biomarin Pharmaceutical's Earnings: A Preview

BioMarin (BMRN) is likely to provide an update on the sales of its key drugs Vimizim, Kuvan and others as well as how the pipeline has progressed when it reports Q2 earnings.

BioMarin (BMRN) to Report Q2 Earnings: What's in the Cards?

Illumina

Vertex Pharmaceuticals

The healthcare industry is a good place to shop for stocks to keep your portfolio healthy during the next market crash.

3 Unstoppable Stocks to Buy Before the Next Market Crash

Galapagos

GW Pharmaceuticals

Binary events could send shares of these stocks screaming higher, or lower, soon.

3 Biotech Stocks With Big Incoming Catalysts

Amgen

Eli Lilly

Regeneron Pharmaceuticals

Seagen

Zoetis

The health care sector has been a big winner in 2020, far outpacing the Dow Jones industrial average and S&P 500.

Goldman Sachs Sees Big Gains From 7 Biotech & Pharma Conviction Buy Stocks

SAN RAFAEL, Calif., July 21, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc.

BioMarin to Host Second Quarter 2020 Financial Results Conference Call and Webcast on Tuesday, August 4 at 4:30pm ET

Five pharmaceutical companies are awaiting approval of drugs in the next few months, and Biomarin Pharmaceutical Inc.

Biomarin’s Hemophilia A Drug Among 5 Up for FDA Approval Soon

SAN RAFAEL, Calif., June 29, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the promotions of Brian R. Mueller to Executive Vice President, Chief Financial Officer and of Andrea L. Acosta to Group Vice President, Chief Accounting Officer. Mr. Mueller had...

BioMarin Promotes Company Veteran, Brian R. Mueller, to Executive Vice President, CFO

Sanofi

Sanofi SA (SNY) has made it clear it wants to get into the rapidly growing gene therapy market, and an acquisition may be the fastest route.

Acquiring Biomarin Would Speed Sanofi Transition to New Therapies

As of late, it has definitely been a great time to be an investor in BioMarin Pharmaceutical.

BioMarin's Shares March Higher, Can It Continue?

Incyte

Lam Research

Zoom Video

In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.

Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF

SAN RAFAEL, Calif., June 17, 2020 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) announced today additional data from its previously reported four-year update of an open-label Phase 1/2 study of valoctocogene roxaparvovec, an investigational gene therapy treatment for severe...

BioMarin Provides Additional Data from Recent 4 Year Update of Ongoing Phase 1/2 Study of Valoctocogene Roxaparvovec Gene Therapy for Severe Hemophilia A in Late-Breaking Oral Presentation at World Federation of Hemophilia Virtual Summit

REGN vs. BMRN: Which Stock Is the Better Value Option?

News for BioMarin Pharmaceutical Stock (BMRN)